Healthineers’ Covid-19 antibody test spikes an interest in vaccines
The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.
Making sense of Covid-19 treatment approaches
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
Zynerba hopes to crack fragile X at last
The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.
Becton Dickinson out for blood with new partnership
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
Olympus banks on acquisitions to sustain its high
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
Avatera Medical becomes the newest robotic surgery group in Europe
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.
Keeping corporations healthy is good business for Livongo
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
Allogene and the need for a reliable cell source
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
Menarini Silicon Biosystems banks on cells for its liquid biopsy
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.
